Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.64
BIOL's Cash to Debt is ranked higher than
60% of the 308 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.60 vs. BIOL: 0.64 )
BIOL' s 10-Year Cash to Debt Range
Min: 0.08   Max: No Debt
Current: 0.64

Equity to Asset 0.31
BIOL's Equity to Asset is ranked higher than
51% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. BIOL: 0.31 )
BIOL' s 10-Year Equity to Asset Range
Min: -0.35   Max: 0.91
Current: 0.31

-0.35
0.91
Interest Coverage No Debt
BIOL's Interest Coverage is ranked higher than
94% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 26.96 vs. BIOL: No Debt )
BIOL' s 10-Year Interest Coverage Range
Min: 10.46   Max: 9999.99
Current: No Debt

10.46
9999.99
F-Score: 2
Z-Score: -3.26
M-Score: -3.34
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -19.49
BIOL's Operating margin (%) is ranked higher than
57% of the 295 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.30 vs. BIOL: -19.49 )
BIOL' s 10-Year Operating margin (%) Range
Min: -357.14   Max: 14.2
Current: -19.49

-357.14
14.2
Net-margin (%) -20.35
BIOL's Net-margin (%) is ranked higher than
57% of the 295 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.08 vs. BIOL: -20.35 )
BIOL' s 10-Year Net-margin (%) Range
Min: -686.67   Max: 39.05
Current: -20.35

-686.67
39.05
ROE (%) -135.38
BIOL's ROE (%) is ranked higher than
50% of the 292 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.68 vs. BIOL: -135.38 )
BIOL' s 10-Year ROE (%) Range
Min: -1471.43   Max: 60.98
Current: -135.38

-1471.43
60.98
ROA (%) -36.99
BIOL's ROA (%) is ranked higher than
53% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.50 vs. BIOL: -36.99 )
BIOL' s 10-Year ROA (%) Range
Min: -264.1   Max: 42.68
Current: -36.99

-264.1
42.68
ROC (Joel Greenblatt) (%) -123.08
BIOL's ROC (Joel Greenblatt) (%) is ranked higher than
56% of the 298 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.70 vs. BIOL: -123.08 )
BIOL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2327.45   Max: 188.13
Current: -123.08

-2327.45
188.13
Revenue Growth (%) 21.30
BIOL's Revenue Growth (%) is ranked higher than
94% of the 276 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. BIOL: 21.30 )
BIOL' s 10-Year Revenue Growth (%) Range
Min: -27.9   Max: 105.4
Current: 21.3

-27.9
105.4
EBITDA Growth (%) -6.40
BIOL's EBITDA Growth (%) is ranked higher than
62% of the 231 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.10 vs. BIOL: -6.40 )
BIOL' s 10-Year EBITDA Growth (%) Range
Min: -49.5   Max: 100
Current: -6.4

-49.5
100
EPS Growth (%) -8.00
BIOL's EPS Growth (%) is ranked higher than
62% of the 237 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.10 vs. BIOL: -8.00 )
BIOL' s 10-Year EPS Growth (%) Range
Min: -54.3   Max: 148.4
Current: -8

-54.3
148.4
» BIOL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

BIOL Guru Trades in Q2 2013

Mario Gabelli 95,475 sh (-5%)
» More
Q3 2013

BIOL Guru Trades in Q3 2013

Mario Gabelli 95,475 sh (-0.5%)
» More
Q4 2013

BIOL Guru Trades in Q4 2013

Mario Gabelli 91,000 sh (-5.16%)
» More
Q1 2014

BIOL Guru Trades in Q1 2014

John Burbank 20,661 sh (New)
Mario Gabelli 91,455 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with BIOL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Burbank 2014-03-31 New Buy$2.279 - $3.343 $ 2.22-21%20661
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 9.30
BIOL's P/B is ranked higher than
53% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.01 vs. BIOL: 9.30 )
BIOL' s 10-Year P/B Range
Min: 0.87   Max: 42.47
Current: 9.3

0.87
42.47
P/S 1.40
BIOL's P/S is ranked higher than
85% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.89 vs. BIOL: 1.40 )
BIOL' s 10-Year P/S Range
Min: 0.13   Max: 9.81
Current: 1.4

0.13
9.81
EV-to-EBIT -6.54
BIOL's EV-to-EBIT is ranked higher than
59% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.19 vs. BIOL: -6.54 )
BIOL' s 10-Year EV-to-EBIT Range
Min: 26.9   Max: 73
Current: -6.54

26.9
73
Current Ratio 1.24
BIOL's Current Ratio is ranked higher than
51% of the 302 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.79 vs. BIOL: 1.24 )
BIOL' s 10-Year Current Ratio Range
Min: 0.63   Max: 8.29
Current: 1.24

0.63
8.29
Quick Ratio 0.61
BIOL's Quick Ratio is ranked lower than
52% of the 302 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.93 vs. BIOL: 0.61 )
BIOL' s 10-Year Quick Ratio Range
Min: 0.34   Max: 7.75
Current: 0.61

0.34
7.75

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 13.90
BIOL's Price/Tangible Book is ranked higher than
60% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.06 vs. BIOL: 13.90 )
BIOL' s 10-Year Price/Tangible Book Range
Min: 3.57   Max: 178.9
Current: 13.9

3.57
178.9
Price/Median PS Value 0.80
BIOL's Price/Median PS Value is ranked higher than
91% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.11 vs. BIOL: 0.80 )
BIOL' s 10-Year Price/Median PS Value Range
Min: 0.23   Max: 33.58
Current: 0.8

0.23
33.58
Earnings Yield (Greenblatt) 2.70
BIOL's Earnings Yield (Greenblatt) is ranked higher than
56% of the 252 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.20 vs. BIOL: 2.70 )
BIOL' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.4   Max: 3.7
Current: 2.7

1.4
3.7
Forward Rate of Return (Yacktman) -8.51
BIOL's Forward Rate of Return (Yacktman) is ranked higher than
62% of the 260 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.95 vs. BIOL: -8.51 )
BIOL' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -1.6   Max: -0.5
Current: -8.51

-1.6
-0.5

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:BTH.Germany
Biolase Inc. was formerly known as BIOLASE Technology, Inc. The Company changed its name to BIOLASE, Inc. in May 2012. It is a medical technology company that develops, manufactures and markets laser systems for dental and medical applications. Its principal product, the Waterlase, is a laser-based hydrokinetic surgical system for cutting hard and soft tissues. The Company's laser products are designed to achieve clinically superior performance with less pain and faster recovery times. Its dental laser systems are used for a broad range of dental procedures, including cosmetic and complex surgical applications. The Company also distributes and markets dental imaging equipment, and Diode Laser systems for numerous therapeutic applications beyond dentistry. The Company sells its products through direct sales personnel and a network of independent distributors. The Company is revolutionizing surgery in dentistry and medicine with WaterLase technology. The Company specializes in the development, manufacturing and marketing of lasers and related products to provide biological treatments that eliminate pain and are safer for patients. BIOLASE leads the global dental industry with laser systems such as the WaterLase iPlus - breaking the speed barrier in dental lasers - and the WaterLase MDX, both featuring BIOLASE patented technologies for eliminating pain and improving clinical results. The Company's unique 940nm wavelength diode laser technology is available in the iLase diode laser system, the world's first totally wireless dental laser, and the ezLase Total Diode Solution for oral surgery as well as teeth whitening and pain relief. The Diolase 10 laser system provides FDA indicated temporary pain relief to chiropractics and sports medicine. The Company's vision for Biological Dentistry goes beyond lasers. Now dentists can SEE MORE dentistry with BIOLASE Imaging and DO MORE dentistry with BIOLASE lasers. BIOLASE is the exclusive distributor for NewTom Cone Beam 3D imaging systems in the U.S. and Canada. NewTom systems are considered among the world's highest quality 3D systems in dentistry and medicine. The BIOLASE DaVinci Imaging D3D 3D x-ray system, with among the lowest radiation of any large field of view CBCT, and many other imaging products improve the speed and accuracy of diagnosis and treatment planning. Other products currently under development address ophthalmology, dermatology, orthopedics, podiatry, and other medical and consumer markets.
» More Articles for BIOL

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
BIOLASE Announces That Non-Executive Board Member Federico Pignatelli Has Withdrawn His Lawsuit... Jul 30 2014
BIOLASE Announces That Non-Executive Board Member Federico Pignatelli Has Withdrawn His Lawsuit... Jul 30 2014
BIOLASE Sends Letter to Stockholders Jul 30 2014
9:04 am Biolase sends letter to stockholders; says 'We urge you to support the Board's five... Jul 30 2014
BIOLASE Sends Letter to Stockholders Jul 30 2014
BIOLASE, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of... Jul 22 2014
BIOLASE to Raise $12 Million from Institutional and Individual Investors in Private Placement Jul 21 2014
BIOLASE sells 6.25M shares at $1.92 in a private placement Jul 21 2014
BIOLASE to Raise $12 Million from Institutional and Individual Investors in Private Placement Jul 21 2014
BIOLASE, INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and... Jul 17 2014
BIOLASE Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) Jul 14 2014
BIOLASE Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) Jul 14 2014
BIOLASE, INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year,... Jun 30 2014
Biolase Director Federico Pignatelli Initiates Process to Obtain Books and Records to Investigate... Jun 27 2014
BIOLASE director initiates process to obtain books to investigate 'wrongdoing' Jun 27 2014
BIOLASE Announces Annual Meeting Date and Record Date Jun 26 2014
BIOLASE Shares Up 25% On Appointments, Resignations & New Committee Jun 17 2014
Why Biolase (BIOL) Stock Is Higher Today Jun 17 2014
BIOLASE, INC Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD... Jun 17 2014
BIOLASE Announces Significant Leadership Changes Jun 17 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide